Skip to main content

back

Press releases

Explore the latest updates and breakthroughs in our research, showcasing key milestones and innovations that are advancing the fields of reproductive medicine and women’s health.

30. September 2025

REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA

Lausanne, Switzerland and Copenhagen, Denmark, September 30, 2025 – ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that China’s National Medical Products Administration (NMPA) has issued a clinical trial approval notice for RPN-001 (leflutrozole). This approval…

REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY

Lausanne, Switzerland and Copenhagen, Denmark, July 1, 2025 – ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administere…

REPRONOVO RAISES $65 MILLION SERIES A FINANCING TO ADVANCE PHASE 2 CLINICAL TRIALS OF NOVEL THERAPIES IN REPRODUCTIVE MEDICINE AND WOMEN’S HEALTH

Lausanne, Switzerland and Copenhagen, Denmark, May 21, 2025 – ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced the successful closing of a $65 million Series A financing round. The round was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Vent…